Multicenter, Open-Label, Phase II Study of Bendamustine and Rituximab Followed by 90-Yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma (Fol-BRITe).

Frederick LansiganCristiana A CostaBassem I ZakiStephanie P YenEric S WinerHelen RyanDarcie FindleySara R MetzlerLynn ShawBonnie ToasoTodd A MacKenzieYoudinghuan ChenAnne W Beaven

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

This report demonstrates that four cycles of BR followed by consolidation with 90YIT achieve high response rates that are durable. In addition, consolidation with 90YIT results in a high conversion rate of PR to CR/CRu. A short course of BR followed by 90YIT is a safe and effective regimen for frontline treatment of FL.

Keyphrases

phase ii study
open label
locally advanced
clinical trial
phase ii
phase iii
diffuse large b cell lymphoma
chronic lymphocytic leukemia
randomized controlled trial
cross sectional
study protocol
squamous cell carcinoma
hodgkin lymphoma
double blind
rectal cancer